Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to $19.5 million.

  • OptimizeRx's Cash & Current Investments rose 2104.06% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year increase of 2104.06%. This contributed to the annual value of $13.4 million for FY2024, which is 340.75% down from last year.
  • Latest data reveals that OptimizeRx reported Cash & Current Investments of $19.5 million as of Q3 2025, which was up 2104.06% from $16.6 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Cash & Current Investments registered a high of $89.0 million during Q1 2022, and its lowest value of $13.4 million during Q4 2024.
  • Its 5-year average for Cash & Current Investments is $52.2 million, with a median of $63.5 million in 2023.
  • As far as peak fluctuations go, OptimizeRx's Cash & Current Investments soared by 70520.66% in 2021, and later plummeted by 8131.69% in 2023.
  • Over the past 5 years, OptimizeRx's Cash & Current Investments (Quarter) stood at $84.7 million in 2021, then decreased by 12.45% to $74.1 million in 2022, then tumbled by 81.32% to $13.9 million in 2023, then dropped by 3.41% to $13.4 million in 2024, then skyrocketed by 45.88% to $19.5 million in 2025.
  • Its last three reported values are $19.5 million in Q3 2025, $16.6 million for Q2 2025, and $16.6 million during Q1 2025.